These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 29195664)
21. Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab. Minor DR; Puzanov I; Callahan MK; Hug BA; Hoos A Pigment Cell Melanoma Res; 2015 Sep; 28(5):611-2. PubMed ID: 25996827 [No Abstract] [Full Text] [Related]
22. Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients. Vanneste L; Wolter P; Van den Oord JJ; Stas M; Garmyn M J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):61-8. PubMed ID: 24661317 [TBL] [Abstract][Full Text] [Related]
23. Acneiform eruption in a patient with metastatic melanoma after ceasing combination dabrafenib/trametinib therapy. Uribe P; Anforth RM; Kefford RF; Fernandez-Peñas P Melanoma Res; 2014 Oct; 24(5):501-3. PubMed ID: 24922191 [TBL] [Abstract][Full Text] [Related]
24. Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma. Dika E; Patrizi A; Ribero S; Fanti PA; Starace M; Melotti B; Sperandi F; Piraccini BM Eur J Dermatol; 2016 Jun; 26(3):232-9. PubMed ID: 27019511 [TBL] [Abstract][Full Text] [Related]
31. Omental actinomycosis imitating a foreign body infection. Choi YS; Park YG Z Gastroenterol; 2017 Jul; 55(7):675-678. PubMed ID: 28709171 [TBL] [Abstract][Full Text] [Related]
32. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF Schreuer M; Jansen Y; Planken S; Chevolet I; Seremet T; Kruse V; Neyns B Lancet Oncol; 2017 Apr; 18(4):464-472. PubMed ID: 28268064 [TBL] [Abstract][Full Text] [Related]
33. Pyoderma Gangrenosum Under Dabrafenib and Trametinib for Metastatic Melanoma. Saint-Jean M; Le Moigne M; Daguze J; Bossard C; Peuvrel L; Quéreux G; Dréno B Acta Derm Venereol; 2018 Apr; 98(5):530-531. PubMed ID: 29362816 [No Abstract] [Full Text] [Related]
34. Rare lesions of the oral cavity: case report of an actinomycotic lesion limited to the gingiva. Sakallioğlu U; Açikgöz G; Kirtiloğlu T; Karagöz F J Oral Sci; 2003 Mar; 45(1):39-42. PubMed ID: 12816363 [TBL] [Abstract][Full Text] [Related]
35. Primary actinomycosis of the breast caused by Actinomyces turicensis with associated Peptoniphilus harei. Abdulrahman GO; Gateley CA Breast Dis; 2015; 35(1):45-7. PubMed ID: 25095985 [TBL] [Abstract][Full Text] [Related]
36. Invasive sinonasal actinomycosis: case report and literature review. Vorasubin N; Wu AW; Day C; Suh JD Laryngoscope; 2013 Feb; 123(2):334-8. PubMed ID: 23008010 [TBL] [Abstract][Full Text] [Related]
37. Dabrafenib in the treatment of metastatic or unresectable melanoma. Khoja L; Hogg D Expert Rev Anticancer Ther; 2015 Mar; 15(3):265-76. PubMed ID: 25711514 [TBL] [Abstract][Full Text] [Related]
38. Agminated melanocytic nevus status post dabrafenib therapy for metastatic melanoma. Agulló A; Hinds B; Santesteban R; Mitxelena JM; Yanguas I Dermatol Online J; 2016 Jul; 22(7):. PubMed ID: 27617734 [TBL] [Abstract][Full Text] [Related]
39. Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors. Menzies AM; Wilmott JS; Drummond M; Lo S; Lyle M; Chan MM; Thompson JF; Guminski A; Carlino MS; Scolyer RA; Kefford RF; Long GV Cancer; 2015 Nov; 121(21):3826-35. PubMed ID: 26218930 [TBL] [Abstract][Full Text] [Related]
40. Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report. Casadevall D; Vidal J; Gallardo F; Zuccarino F; Arumí-Uría M; Dalmases A; Bellosillo B; Montagut C J Med Case Rep; 2016 Jun; 10(1):158. PubMed ID: 27255157 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]